Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa

Klinkenberg‐Knol, Elly C.; Nelis, Frits; Dent, John; Snel, P.; Mitchell, B.; Prichard, Peter J; Lloyd, David; Havu, Niilo; Frame, Madeline H.; Román, Jonas; Walan, A

doi:10.1016/s0016-5085(00)70135-1

Cited by 497 publications

(345 citation statements)

References 32 publications

Supporting

Mentioning

292

Contrasting

Unclassified

Order By: Relevance

“…High incidence rates of CAG were furthermore, observed in cohorts of H. pylori positive patients treated with omeprazole for reflux esophagitis [14,20,22]. This finding might be explained by the joint impact of long-term H. pylori infection and omeprazole therapy on lowering of the gastric acidity which makes the gastric mucosa more prone to atrophy.…”

Section: Discussionmentioning

confidence: 93%

“…Another 4 articles were excluded for the following reasons: all patients had either chronic gastritis or CAG at baseline, incidence of CAG was based on biopsies and not on study participants, incidence of CAG and metaplasia or either of them were grouped together and in one study, no mean follow-up time could be estimated. Due to these exclusions, only 14 studies (from 15 articles) with information on the incidence of CAG could be included in this review [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. According to the above described criteria, all of these studies included more than 15 study participants who were diagnosed to be free of CAG at baseline, either by histology ('normal' or 'superficial gastritis') or by serum pepsinogen (PG) levels.…”

Section: Resultsmentioning

confidence: 99%

“…The most recent one in 1990-1993 in Slovenia; [19] all studies were published between 1988 and 2008. 2 of the studies were conducted in multiple centres in different countries [20,22]. Studies were carried out in Sweden, [10] Columbia, [11] the Netherlands, [12,13] the Netherlands and Sweden, [14] Finland, [15] Estonia, [16,24] Japan, [17,23] USA, [18] Slovenia, [19] Australia, Canada, Germany, and the Netherlands, [20] Germany [21] and Denmark, Finland, Norway and Sweden [22].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

et al. 2010

View full text Add to dashboard Cite

Chronic atrophic gastritis (CAG) is an important precursor lesion of intestinal gastric cancer. As it is typically asymptomatic, epidemiological data on the incidence of CAG are sparse. We aimed to provide an overview of published data on CAG incidence (overall and according to risk factors) from follow-up studies. Articles with information on incidence of CAG published in English until 26th of July 2009 were identified through a systematic MEDLINE and EMBASE search. Data extracted include study characteristics and key findings regarding the incidence of CAG. A meta-analysis was performed on the association between Helicobacter pylori infection and CAG incidence. Overall, data on CAG incidence were available from 14 studies, in 7 studies incidence could be estimated according to H. pylori infection. Most studies were conducted in symptomatic or high risk populations and the maximum number of incident cases was 284. Incidence estimates ranged from 0 to 11% per year and were consistently below 1% in patients not infected with H. pylori. The highest incidence was observed in a special study conducted on ulcer patients treated by proximal gastric vagotomy. Rate ratios for the association between H. pylori infection and CAG incidence ranged from 2.4 to 7.6 with a summary estimate of 5.0 (95% confidence interval: 3.1-8.3). Incidence of CAG is very low in the absence of H. pylori infection. There is a need for more population-based studies to provide comparable estimates of incidence and the impact of risk factors in the development of CAG.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Most studies have found an annual increase in corpus atrophy in H. pylori-infected patients on PPIs compared with those receiving no treatment (99,100). One study has indicated that H. pylori-infected patients with the highest serum levels of gastrin before PPI therapy showed the most marked progression in gastric atrophy during PPI therapy (99).…”

Section: Role Of Acid-suppressive Drugs In the Development Of Atrophymentioning

confidence: 99%

Inflammation, atrophy, and gastric cancer

Fox

Wang²

2007

J. Clin. Invest.

694

626

View full text Add to dashboard Cite

The association between chronic inflammation and cancer is now well established. This association has recently received renewed interest with the recognition that microbial pathogens can be responsible for the chronic inflammation observed in many cancers, particularly those originating in the gastrointestinal system. A prime example is Helicobacter pylori, which infects 50% of the world's population and is now known to be responsible for inducing chronic gastric inflammation that progresses to atrophy, metaplasia, dysplasia, and gastric cancer. This Review provides an overview of recent progress in elucidating the bacterial properties responsible for colonization of the stomach, persistence in the stomach, and triggering of inflammation, as well as the host factors that have a role in determining whether gastritis progresses to gastric cancer. We also discuss how the increased understanding of the relationship between inflammation and gastric cancer still leaves many questions unanswered regarding recommendations for prevention and treatment.

show abstract

“…In a study of 230 patients with oesophagitis treated with omeprazole and followed up for 11.2 years, the initial dosage needs varied; however, following calibration to the minimally effective maintenance dose in the first year, few then required an increase in the dose over the follow-up period. 6 Choice of medication based on safety Both H 2 RAs and proton pump inhibitors have remarkably good safety profiles. One issue that has been raised in relation to maintenance proton pump inhibitor therapy has been the association between progression of gastritis to atrophic gastritis and continued potent gastric acid suppression.…”

Section: Choice Of Medication Based On Efficacymentioning

confidence: 99%

Overview: initial and long‐term management of gastro‐oesophageal reflux disease

Talley

2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Initial management of gastro‐oesophageal reflux disease aims to confirm a symptom‐based diagnosis, to relieve symptoms, to reassure the patient as to the treatable nature of reflux disease, and to initiate risk management and healing of oesophagitis. The aims of long‐term management include adequate control of symptoms, prevention of complications, and improvement of quality of life. Management options in terms of use of proton pump inhibitors are either daily therapy (maintenance), intermittent courses of therapy (for example, 4 weeks, then cease and observe), or on‐demand therapy. This overview discusses the advantages and disadvantages of these different strategies for the management of reflux disease.

show abstract

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa

Cited by 497 publications

References 32 publications

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies

Inflammation, atrophy, and gastric cancer

Overview: initial and long‐term management of gastro‐oesophageal reflux disease

Contact Info

Product

Resources

About